Editorial use only.
Humira injection. Close-up of a pre-filled syringe containing a dose of the drug adalimumab, marketed under the name Humira, used for self-administration. Adalimumab is a human monoclonal antibody that targets excess tumour necrosis factor (TNF) in the body, overproduction of which causes inflammation, swelling, and pain. It is used for the treatment of autoimmune diseases such as rheumatoid and psoriatic arthritis, Crohn's disease and ulcerative colitis.
Model release not required. Property release not available.